These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35678582)

  • 21. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
    He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a benefit for
    van den Broek WW; Ten Berg JM
    Pharmacogenomics; 2021 Aug; 22(12):727-730. PubMed ID: 34251288
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
    Jiang M; You JH
    Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
    Collet JP; Kerneis M; Hulot JS; O'Connor SA; Silvain J; Mansencal N; Brugier D; Abtan J; Barthélémy O; Vignalou JB; Payot L; Rousseau H; Vicaut E; Montalescot G;
    Thromb Haemost; 2016 Jan; 115(2):382-91. PubMed ID: 26423110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
    Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
    Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
    Klein MD; Lee CR; Stouffer GA
    Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
    Jiang M; You JH
    Expert Opin Pharmacother; 2015 Apr; 16(5):771-9. PubMed ID: 25660101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
    Claassens DMF; van Dorst PWM; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Postma MJ; Deneer VHM; Ten Berg JM; Boersma C
    Am J Cardiovasc Drugs; 2022 Mar; 22(2):195-206. PubMed ID: 34490590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes and Sustainability of Using
    Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
    Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Maamari DJ; Jaffer FA; Khera AV; Fahed AC
    Circulation; 2022 Mar; 145(10):721-723. PubMed ID: 35254917
    [No Abstract]   [Full Text] [Related]  

  • 34. Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates.
    Comanici M; Raja SG
    Am J Cardiol; 2023 Sep; 203():507-508. PubMed ID: 37500316
    [No Abstract]   [Full Text] [Related]  

  • 35. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
    Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J
    Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
    Tan DS; Aw JWX; Winther M; Goh LL; Ong HY; Wee E; Liu J; Ho HK
    J Clin Pharm Ther; 2020 Feb; 45(1):52-58. PubMed ID: 31670842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.
    Sánchez-Ramos J; Dávila-Fajardo CL; Toledo Frías P; Díaz Villamarín X; Martínez-González LJ; Martínez Huertas S; Burillo Gómez F; Caballero Borrego J; Bautista Pavés A; Marín Guzmán MC; Ramirez Hernández JA; Correa Vilches C; Cabeza Barrera J
    Int J Cardiol; 2016 Dec; 225():289-295. PubMed ID: 27744205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.